Following an advisory panel recommendation on July 6, the US Food and Drug Administration has approved, under Priority Review, single-dose Krintafel (tafenoquine) for the radical cure (prevention of relapse) of Plasmodium vivax (P. vivax)malaria in patients aged 16 years and older who are receiving appropriate antimalarial therapy for acute P. vivax infection.
{iframe}https://www.thepharmaletter.com/article/fda-priority-approval-for-gsk-malaria-relapse-drug{/iframe}